IL-21 antibody (Biotin)

Catalog No. ABIN2666224

The Mouse Monoclonal anti-IL-21 antibody has been validated for ICFC. It is suitable to detect IL-21 in samples from Human and Mouse.

Quick Overview for IL-21 antibody (Biotin) (ABIN2666224)

Target: IL-21 (IL21) (Interleukin 21 (IL21))

Reactivity: Human, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL-21 antibody is conjugated to Biotin

Application: Intracellular Flow Cytometry (ICFC)

Clone: 7H20-I19-M3

Product Details anti-IL-21 Antibody (Biotin)

Cross-Reactivity (Details): Mouse* - weak affinity

Purification: The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide. Final antibody concentration is 0.5 mg/mL.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Upon receipt, store frozen between 2°C and 8°C.

Target Details for IL-21

Target: IL-21 (IL21) (Interleukin 21 (IL21))

Alternative Name: IL-21

Background: Interleukin 21 (IL-21) is a potent immunomodulatory cytokine mainly produced by NKT and CD4+ T-cells, particularly the inflammatory Th17 subset and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhancing proliferation of NK cells and cytotoxic T cells, and inhibitory effects on the antigen-presenting function of dendritic cells. It can also be proapoptotic for B cells and NK cells. Recent studies have shown that IL-21 is also an autocrine cytokine that potently induces T(H)17 differentiation and suppresses Foxp3 expression, and serves as a target for treating inflammatory diseases.

Pathways: JAK-STAT Signaling, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response